MTOR and prostate cancer: It has been shown that simultaneous targeting of the AR and the PI3K/mTOR signaling pathway may be clinically beneficial to LAR TNBC patients [6,7,58,59], as this combination has been shown to be synergistic in AR-dependent prostate cancer cells in clinical trials [60].However, the role of AR in TNBC is still not fully understood, especially in mesenchymal stem-like (MSL) TNBC cells.